Drugs Containing Excipient (Inactive Ingredient) CYSTEINE

Branded drugs containing CYSTEINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mallinckrodt ARD LLC	ACTHAR	repository corticotropin	63004-8710	CYSTEINE
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	CYSTEINE HYDROCHLORIDE	2032-05-26
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	CYSTEINE HYDROCHLORIDE	2030-04-02
Hikma Pharmaceuticals USA Inc	COMBOGESIC IV	acetaminophen and ibuprofen injection	0143-9150	CYSTEINE HYDROCHLORIDE	2026-10-17
GlaxoSmithKline LLC	WELLBUTRIN	bupropion hydrochloride	0173-0947	CYSTEINE HYDROCHLORIDE

Generic drugs containing CYSTEINE excipient

Company	Ingredient	NDC	Excipient
Mallinckrodt ARD LLC	repository corticotropin	63004-8710	CYSTEINE
Abeona Therapeutics Inc	prademagene zamikeracel	84103-007	CYSTEINE
A-S Medication Solutions	bupropion hydrochloride	50090-4747	CYSTEINE HCL
A-S Medication Solutions	bupropion hydrochloride	50090-6789	CYSTEINE HCL
A-S Medication Solutions	bupropion hydrochloride	50090-7602	CYSTEINE HCL

Market Dynamics and Financial Trajectory for Cysteine as a Pharmaceutical Excipient

Last updated: February 20, 2026

What Is Cysteine and Its Role as a Pharmaceutical Excipient?

Cysteine is a semi-essential amino acid used in pharmaceutical manufacturing primarily as a stabilizer, antioxidant, and reducing agent. It is commercially produced through chemical synthesis or microbial fermentation. Its applications span from biopharmaceuticals to dietary supplements, with increasing demand driven by rising biologic drug formulations.

Industry Overview and Market Size

The global cysteine market was valued at approximately USD 580 million in 2021 and is projected to reach USD 800 million by 2030. Compound annual growth rate (CAGR) is estimated at 4.2% from 2022 to 2030. Growth factors include increased biologic drugs requiring stability agents, expanding dietary supplement markets, and the rising prevalence of chronic diseases.

Year	Market Size (USD million)	CAGR (%, 2022-2030)
2021	580	—
2025	690	4.0%
2030	800	4.2%

Major players comprise Ajinomoto, AVANTOR, and Norm Enterprises. North America and Asia-Pacific account for the largest market shares, driven by technological advances and increased manufacturing capacity.

Supply Chain and Production Dynamics

Production relies on two main processes:

• Chemical synthesis via the hydrogen sulfide method.
• Microbial fermentation of carbohydrate substrates, more sustainable but cost-intensive.

The chemical synthesis route dominates the market, representing roughly 85% of production capacity. Key suppliers are investing in capacity expansion, especially in China and India, to meet rising demand.

Market Drivers

• Biologics and biosimilars: Require cysteine for protein stabilization, increasing demand.
• Dietary supplements: Growing health consciousness enhances consumption of amino acid supplements containing cysteine.
• Regulatory support: Favorable policies for generic and biosimilar drugs expand applications.

Market Challenges

• High production costs: Especially for fermentation-based processes.
• Regulatory constraints: Food and pharmaceutical safety standards require strict compliance, impacting manufacturing costs.
• Pricing pressures: Competition and procurement policies in emerging markets exert downward pressure on prices.

Financial Trajectory and Investment Outlook

Investments are focused on process optimization, particularly shifting towards sustainable microbial fermentation. Capital expenditure in 2021 reached USD 150 million globally, with a regional distribution favoring Asia. Margins vary, with chemical synthesis products averaging 15% and fermentation-based cysteine achieving around 25% gross margin due to higher quality standards and differentiation.

Forecasts indicate an incremental increase in profitability, especially among integrated suppliers. Market expansion is contingent upon capacity upgrades, technological breakthroughs, and regulatory approvals.

Key Market Segments

Segment	Share (%)	Growth Drivers	Notes
Biological drugs	45	Increased biologic formulations	Demand for cysteine as stabilizer
Dietary supplements	25	Rising health awareness	Increased intake of amino acids
Food processing	15	Use as flavor enhancer and preservative	Smaller segment
Personal care	10	Emerging applications	Niche but growing

Regulatory Landscape

Regulations from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China Food and Drug Administration (CFDA) govern manufacturing standards. Compliance influences market access and pricing strategies.

Conclusion

The cysteine market for pharmaceuticals exhibits steady growth driven by biopharmaceutical needs and supplement markets. Production costs and regulatory requirements are key factors influencing profitability. Technological advancements hold potential for market expansion and margin improvement.

Key Takeaways

• The global cysteine market is projected to grow at a CAGR of 4.2% until 2030, reaching USD 800 million.
• Dominant applications include biologic drug stabilization and dietary supplements.
• Production is primarily chemical synthesis, with increased investment in microbial fermentation.
• Regulatory compliance and cost management are critical for market players.
• Innovation in sustainable manufacturing has the potential to influence future market dynamics.

FAQs

Q1: What are the primary applications of cysteine in pharmaceuticals?
Cysteine serves mainly as a stabilizer, antioxidant, and reducing agent in biologic drugs and formulations.

Q2: Which regions dominate the cysteine market?
North America and Asia-Pacific lead due to advanced manufacturing and expanding demand, notably in China and India.

Q3: How is the market impacted by regulatory policies?
Strict standards from FDA, EMA, and CFDA influence manufacturing costs, quality control, and market access.

Q4: What technological developments could impact future growth?
Advances in microbial fermentation and sustainable synthesis methods can reduce costs and meet regulatory standards more efficiently.

Q5: Who are the key players in the cysteine market?
Ajinomoto, AVANTOR, and Norm Enterprises are primary suppliers, with ongoing capacity expansion investments.

---

References

[1] MarketsandMarkets. (2022). Cysteine market analysis.
[2] Transparency Market Research. (2021). Global amino acids market.
[3] U.S. Food and Drug Administration. (2020). Pharmaceutical excipients standards.
[4] European Medicines Agency. (2021). Biopharmaceutical excipient guidelines.
[5] China Food and Drug Administration. (2020). Regulatory framework for amino acids.